EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study

Fabrizio Oliva, Francesco Orso, Furio Colivicchi, Manlio Gianni Cipriani, Andrea DI Lenarda, Domenico Gabrielli, Mauro Gori, Marco Gorini, Massimo Iacoviello, Donata Lucci, Marco Marini, Francesco Amico und 16 weitere

Journal of Cardiac Failure · 2025-12 · 31 (12) · 1847-1857

DOI: 10.1016/j.cardfail.2025.02.019 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cardiac Failure, 2025-12. Verfasst von Fabrizio Oliva und 27 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit. Niguarda Hospital, Milano, Italy. Hauptthemen laut MEDLINE: Heart Failure, Benzhydryl Compounds, Glucosides, Ambulatory Care. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma, Boehringer Ingelheim, Heart Care Foundation of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Current European Society of Cardiology guidelines introduced a 4-pillar approach for the treatment of HFrEF and a class IA recommendations for empagliflozin and dapagliflozin in HFmrEF and HFpEF. OBJECTIVES: The BRING-UP-3 Heart Failure (HF) study was designed to guide the Guideline-implementation recommendations for patients with HF enrolled in a large sample of Italian cardiology sites. METHODS: The BRING-UP-3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites and enrolling ambulatory and hospitalized patients with HF. The study includes an educational intervention followed by 2 3-month enrolment periods and by a 6-month follow-up period with end-point evaluation. For patients with HFrEF, the objective is to describe the proportion of patients who receive the 4 pillars. Here we present the baseline data of the ambulatory cohort. RESULTS: A total of 3830 ambulatory patients were included in the study. The mean age was 70 ± 12 years (34.5% older than 75 years), females were 21.9%. The most prevalent group was HFrEF (58.4%), followed by HFimpEF (17.4%), HFmrEF (14.4%), and HFpEF (9.8%). Hypertension, atrial fibrillation, diabetes mellitus, and chronic kidney disease were reported in 68.2%, 40.4%, 31.0%, and 33.1%, respectively. In patients with HFrEF, a high prescription rate (65%) for the 4 therapeutic pillars was observed; beta-blockers and RASis (mostly ARNIs) were prescribed in over 90%, while SGLT2is and MRAs were prescribed in over 80% of cases. In HFmrEF and HFpEF, SGLT2i prescription rates reached 72.1% and 50.1%, respectively. CONCLUSIONS: A comprehensive analysis of a large sample of Italian cardiology sites revealed a high prevalence of prescription of guideline-recommended treatments. CLINICALTRIAL: GOV: NCT06279988.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureBenzhydryl CompoundsGlucosidesAmbulatory CareHumansFemaleMaleAgedProspective StudiesItalyMiddle AgedFollow-Up StudiesSodium-Glucose Transporter 2 InhibitorsAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Chronic heart failureadherenceguidelinesmedical treatmentsregistry

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesdapagliflozin

Autor:innen und Institutionen

  • Cardiology Unit. Niguarda Hospital, Milano, Italy.
  • ANMCO Research Center, Heart Care Foundation, Firenze, Italy.
  • Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Roma, Italy.
  • Cardiology Unit, ISMETT-IRCCS, Palermo, Italy.
  • Cardiovascular Center, University Hospital and Health Services of Trieste, Trieste, Italy.
  • ANMCO Research Center, Heart Care Foundation, Firenze, Italy; Department of Cardio-Thoracic and Vascular Medicine and Surgery, Division of Cardiology, A.O. San Camillo-Forlanini, Roma, Italy.

Förderung

  • Novartis Pharma
  • Boehringer Ingelheim
  • Heart Care Foundation of India

Zitieren

APA

Oliva, F., Orso, F., Colivicchi, F., Cipriani, M. G., DI Lenarda, A., Gabrielli, D., Gori, M., Gorini, M., Iacoviello, M., Lucci, D., Marini, M., Amico, F., Bertoli, D., Carigi, S., D'Elia, E., DI Fusco, S. A., Fucili, A., Lanati, G., Menegato, A., …, & on the behalf of BRING-UP-3 Heart Failure Investigators (2025). Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study. Journal of Cardiac Failure, 31(12), 1847-1857. https://doi.org/10.1016/j.cardfail.2025.02.019

Vancouver

Oliva F, Orso F, Colivicchi F, Cipriani MG, DI Lenarda A, Gabrielli D, et al. Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study. Journal of Cardiac Failure. 2025;31(12):1847-1857. doi:10.1016/j.cardfail.2025.02.019

BibTeX
@article{Oliva2025,
  author = {Oliva, Fabrizio and Orso, Francesco and Colivicchi, Furio and Cipriani, Manlio Gianni and DI Lenarda, Andrea and Gabrielli, Domenico and Gori, Mauro and Gorini, Marco and Iacoviello, Massimo and Lucci, Donata and Marini, Marco and Amico, Francesco and Bertoli, Daniele and Carigi, Samuela and D'Elia, Emilia and DI Fusco, Stefania Angela and Fucili, Alessandro and Lanati, Gianluca and Menegato, Alessandra and Moretti, Michele and Navazio, Alessandro and Passantino, Andrea and Pulignano, Giovanni and Ruzzolini, Matteo and Scardovi, Angela Beatrice and Somaschini, Alberto and Maggioni, Aldo Pietro and on the behalf of BRING-UP-3 Heart Failure Investigators, on the behalf of BRING-UP-3 Heart Failure Investigators},
  title = {Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  volume = {31},
  number = {12},
  pages = {1847--1857},
  doi = {10.1016/j.cardfail.2025.02.019}
}
Kostenlos starten →